Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$9.14
+10.4%
$8.71
$2.31
$13.70
$29.09M-0.63119,712 shs116,853 shs
CEL-SCI Co. stock logo
CVM
CEL-SCI
$2.80
+14.8%
$3.79
$1.98
$66.60
$7.40M0.381,389 shs337,283 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$2.09
-0.5%
$1.74
$0.51
$2.60
$28.70M1.66260,035 shs155,802 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$7.52
+1.1%
$6.91
$5.35
$30.03
$27.40M-1.95166,060 shs70,799 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
+10.39%+22.19%+4.46%-2.77%+65.58%
CEL-SCI Co. stock logo
CVM
CEL-SCI
+14.75%+11.11%+10.24%-55.75%-92.41%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-0.48%+10.00%+10.00%+111.39%+124.71%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
+1.08%+5.47%-15.98%+28.33%-73.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.2032 of 5 stars
0.03.00.00.00.01.70.0
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.082 of 5 stars
0.02.00.00.00.00.00.6
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.8527 of 5 stars
3.53.00.00.00.61.70.0
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.7137 of 5 stars
3.32.00.00.02.20.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.00
N/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
3.00
Buy$14.00569.86% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2.50
Moderate Buy$30.00298.94% Upside

Current Analyst Ratings Breakdown

Latest CVM, COEP, TPST, and NRSN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$16.00 ➝ $16.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/A$1.61 per shareN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A$0.19 per shareN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$5.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$10.88M-$5.80N/AN/AN/A-282.39%-127.23%N/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$10.21M-$0.54N/AN/AN/AN/A-445.40%N/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$41.84M-$17.98N/AN/AN/AN/A-305.51%-119.74%8/14/2025 (Estimated)

Latest CVM, COEP, TPST, and NRSN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/A-$1.11N/A-$1.11N/AN/A
5/13/2025Q1 2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.71-$3.16+$0.55-$3.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.02
0.82
0.82
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
2.21
2.21
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
1.70
1.70

Institutional Ownership

CompanyInstitutional Ownership
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
13.88%
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
24.25%
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
23.51 million2.66 millionNot Optionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
433.03 million64.67 millionOptionable
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1013.67 million9.92 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
203.68 million3.51 millionOptionable

Recent News About These Companies

Tempest Therapeutics (NASDAQ:TPST) Trading Up 0.2% - Here's Why
TPST Tempest Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Coeptis Therapeutics stock logo

Coeptis Therapeutics NASDAQ:COEP

$9.14 +0.86 (+10.39%)
Closing price 07/9/2025 03:59 PM Eastern
Extended Trading
$9.30 +0.15 (+1.70%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$2.80 +0.36 (+14.75%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$2.84 +0.04 (+1.39%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$2.09 -0.01 (-0.48%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$2.15 +0.06 (+2.92%)
As of 07:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$7.52 +0.08 (+1.08%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$7.48 -0.04 (-0.53%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.